Journal
THERAPEUTIC DELIVERY
Volume 1, Issue 2, Pages 273-287Publisher
FUTURE SCI LTD
DOI: 10.4155/TDE.10.24
Keywords
-
Categories
Funding
- State Key Development Plan Project [2006CB10901, 2007CB935801, 2006CB933305]
- National Natural Science Foundation of China [90606019, 30901869]
- Chinese Academy of Sciences Project [KSCX1-YW-R-21]
- China-Finland Inter-Governmental S&T cooperation project [2008DFA01510]
- National Science and Technology Special Project of Major New Drugs Creation [2009ZX09501-025]
Ask authors/readers for more resources
Doxorubicin (DOX) is one of the most active anticancer drugs, while its cumulative dose-dependent side effects compromise the anticancer efficacy. Nanoparticles, an emerging platform for cancer therapy, have been shown to increase intracellular uptake of DOX with reduced side effects compared with conventional DOX formulations. While large numbers of clinical and preclinical studies have been published, the purpose of this review is to draw attention to the developments of DOX-loaded nanoparticles for cancer therapy, with special a focus on enhanced intracellular uptake and reduced side-effects strategies.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available